Sinovac Biotech's Albumin-Bound Paclitaxel (Apexelsin®) Approved for Market Launch in Uruguay

(Source:Kexing Biopharm）

Source: Kexing Biopharm

Recently, Apexelsin® (Albumin-bound Paclitaxel for Injection), a collaborative product between Kexing Biopharm and Haichang Biotech, has received marketing approval from Uruguay's Ministry of Public Health (MSP). This marks another milestone for Kexing Biopharm in the South American market and brings a new treatment option to cancer patients in Uruguay.

Injectable Paclitaxel (Albumin-Bound) Formulation Offers Clinical Advantages Over Conventional Paclitaxel Injection and Paclitaxel Liposome, With Improved Safety and Patient Compliance, Gaining High Clinical Recognition; In 2023, Global Sales of Injectable Paclitaxel (Albumin-Bound) Reached $2.397 Billion. In Recent Years, the Global Cancer Incidence Has Been on the Rise, Driving Steady Growth in Market Demand for Premium Oncology Drugs.

It is understood that the diseases with high mortality rates in Uruguay are mainly cardiovascular diseases and malignant tumors, leading to a significant demand for high-quality anti-cancer drugs. At the same time, Uruguay prefers imported drugs with EU-level GMP certification. Therefore, Kexing Biopharm's albumin paclitaxel, a major anti-cancer product that has already been marketed in the EU, was quickly approved after submitting the product registration documents in Uruguay. This once again highlights the clinical value of the product and Kexing’s efficient overseas commercialization capabilities!

In recent years, Uruguay has experienced rapid economic growth, with a GDP increase of 3.1% in 2024, placing its per capita GDP at the forefront among Latin American countries. Additionally, due to its excellent strategic geographical location, Uruguay's position as a logistics hub for the pharmaceutical industry in Latin America has gradually solidified, attracting several world-leading pharmaceutical companies to establish regional distribution centers in the country.

In May this year, Kexing Biopharm's Apexelsin® was approved in Peru. This approval in the second market in South America will further expand the company's coverage of the South American pharmaceutical market.

In the future, Kexing Biopharm will leverage Uruguay's regional advantages to deepen cooperation with the local healthcare system, enabling innovative drugs to benefit more patients. At the same time, it will continue to expand into global markets, promoting the development of global health through pharmaceutical innovation.

About Kexing Biopharm

Kexing Biopharm (Stock Code: 688136) is an innovative multinational biopharmaceutical company that integrates the research, production, and sales of drugs such as recombinant proteins, multi-functional antibodies, and cell and gene therapies. Focusing on therapeutic areas like anti-tumor, autoimmune, and antiviral treatments, the company addresses unmet clinical needs by developing novel proteins, new antibodies, and nucleic acid drugs.Frontier BiotechTechnical platform, developing precision treatments and novel targeted delivery drugs, adhering to a "innovation + internationalization" dual-driven platform development model, committed to becoming a leader in high-quality biopharmaceuticals and serving patients worldwide.The company's core products rank among the top in China for similar varieties, covering approximately 20,000 terminals across all provinces and regions in China, including about 8,000 graded hospitals. Market access has been achieved and sales realized in more than 70 countries worldwide, including the EU, Brazil, the Philippines, and Indonesia.